obesity-995x60.png
FEATURED ARTICLES
What Really Happens At The Site When Sponsors Pull Back Mid-Trial
When sponsors slow or reduce operational spending due to financial pressure, strategic pivots, or internal restructuring, sites — and patients — suffer. Curo Research CCO Amy Bland explains how sponsors can better manage operational changes.
-
One Drug, Three Indications: How Small ClinOps Teams Manage Multi-Trial Execution
Having the same number of clinical programs as team members might sound crazy, but for Step Pharma, it has become one of their biggest strengths.
-
Rare Disease Nonprofits: De-Risk Development With Orphan Drug Designation And Early Talks With The FDA
For nonprofit organizations, Orphan Drug Designation is the start of a disciplined, forward-looking regulatory strategy, but it's not the only factor in success. H. Greg Thomas, Ph.D., shares his advice for de-risking orphan drug development.
-
Participants Don't Care How Your Vendor Stack Works
Participants experience one study, not the vendor stack behind it. Learn how sponsors and CROs can reduce burden with support built around real study needs.